Boston Scientific has acquired Nalu Medical for $600 million to enhance its neuromodulation portfolio for chronic pain management.

Target Information

Boston Scientific Corporation (NYSE: BSX) has successfully completed the acquisition of Nalu Medical for $600 million. This strategic move enhances Boston Scientific's neuromodulation portfolio, particularly for chronic pain management. Nalu Medical is renowned for its innovative miniaturized, battery-free implantable pulse generator, which offers spinal cord and peripheral nerve stimulation solutions. This technology is distinguished by its wireless power supply, controlled via smartphone, and is anticipated to deliver an impressive service life of up to 18 years. Originally cleared by the FDA in 2019, this system has also received approval for full-body MRI usage, showcasing its versatility and advanced capabilities.

With the acquisition, Boston Scientific aims to tap into a market where Nalu's revenues are projected to exceed $60 million in 2025, with expectations of a growth rate exceeding 25% in 2026. The company anticipates that this transaction will contribute positively to its earnings beginning in 2027, indicating a well-calculated investment in a growing sector.

Industry Overview

The neuromodulation industry in the United States is experiencing rapid growth, driven by increasing prevalence of chronic pain conditions, advancements in technology, and the rising acceptance of minimally invasive procedures. As the population ages and more individuals seek effectiv